Browsing Category
Pharma Industry News
4753 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Outlook Therapeutics trims workforce by 23% to fund Lytenava launch
Outlook Therapeutics, a biopharmaceutical company specialising in retina disease treatments, has announced a 23% workforce reduction as part…
FDA approves Checkpoint Therapeutics’ Unloxcyt for advanced cSCC
Shares of Checkpoint Therapeutics, Inc. rose 4.6% to $3.84 in post-market trading after the US Food and Drug…
FDA approves CRENESSITY: A breakthrough treatment from Neurocrine Biosciences for classic congenital adrenal hyperplasia
Neurocrine Biosciences has announced US Food and Drug Administration (FDA) approval of CRENESSITY, marking a significant milestone in…
Merck’s WELIREG receives positive CHMP opinion for VHL tumours and advanced RCC
Merck, known as MSD outside the U.S. and Canada, has moved a step closer to offering innovative treatment…
Aptevo Therapeutics achieves major breakthrough with mipletamig in acute myeloid leukemia
Aptevo Therapeutics has unveiled remarkable findings from Cohort 1 of its RAINIER clinical trial for mipletamig, a bispecific…
Trevi Therapeutics announces positive results for Haduvio in Phase 2b CORAL study
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, has reported a positive outcome from the planned sample size re-estimation…
Keros Therapeutics adjusts TROPOS trial of cibotercept amid safety concerns
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced significant changes to its Phase 2 TROPOS trial evaluating…
Eli Lilly achieves breakthrough with Imlunestrant in Phase 3 breast cancer trial
Eli Lilly and Company has announced encouraging results from its Phase 3 EMBER-3 study evaluating imlunestrant, an investigational…
AnaptysBio abandons eczema drug after trial failures; shares nosedive
Biotechnology company AnaptysBio, Inc., specializing in innovative autoimmune disease therapies, announced it will halt development of its atopic…
UniQure shares surge as FDA aligns on accelerated approval pathway for AMT-130 in Huntington’s disease
UniQure, Huntington’s disease, gene therapy, FDA, accelerated approval pathway, regenerative medicine designation, AMT-130, Biologics License Application, neurodegenerative diseases, cUHDRS, Phase I/II studies, neurofilament light chain, Lexington biotech